Journal article that states providers should use prescribing information, guidelines, pharmacokinetic properties, reliable estimation of kidney function and clinical judgment to optimize antiplatelet and antithrombotic drug therapy in chronic kidney disease (CKD). Individualized factors such as stage of CKD, mode of administration, adherence, frequency of dosing, drug/drug interactions, drug/disease interactions, requirements for laboratory monitoring, cost and patient/caretaker preference must also be considered.
